Glaukos Corporation
$123.8
▲
1.38%
2026-04-22 10:12:13
www.glaukos.com
NYQ: GKOS
Explore Glaukos Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.27 B
Current Price
$123.8
52W High / Low
$130.23 / $73.16
Stock P/E
—
Book Value
$11.41
Dividend Yield
—
ROCE
-25.2%
ROE
-26.38%
Face Value
—
EPS
$-3.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
1,094
Beta
0.78
Debt / Equity
16.24
Current Ratio
4.69
Quick Ratio
4.06
Forward P/E
269.14
Price / Sales
13.32
Enterprise Value
$6.58 B
EV / EBITDA
-135.38
EV / Revenue
12.98
Rating
Strong Buy
Target Price
$138.92
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ENvue Medical, Inc. | $1.51 | — | $5.59 M | — | -394.93% | -30.51% | $75.48 / $0.99 | $42 |
| 2. | TriSalus Life Sciences, Inc. | $4.6 | — | $285.58 M | — | -113.07% | 131.29% | $7.95 / $3.42 | $-0.68 |
| 3. | Xtant Medical Holdings, Inc. | $0.5 | 15.1 | $75.1 M | — | 11.26% | 10.59% | $0.95 / $0.39 | $0.36 |
| 4. | RxSight, Inc. | $7.44 | — | $314.04 M | — | -16.88% | -13.98% | $16.74 / $5.9 | $6.68 |
| 5. | Cerus Corporation | $2.05 | — | $397.8 M | — | -7.17% | -25.66% | $2.96 / $1.15 | $0.33 |
| 6. | Modular Medical, Inc. | $5.41 | — | $27.31 M | — | -109.03% | -3.32% | $34.5 / $3.55 | $2.27 |
| 7. | AdaptHealth Corp. | $12.67 | — | $1.72 B | — | 5.17% | -4.25% | $12.87 / $7.11 | $11.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 143.12 M | 133.54 M | 124.12 M | 106.66 M | 105.5 M |
| Operating Profit | -139.87 M | -16.36 M | -22.69 M | -20.68 M | -28.67 M |
| Net Profit | -133.66 M | -16.23 M | -19.66 M | -18.15 M | -33.58 M |
| EPS in Rs | -2.3 | -0.28 | -0.34 | -0.31 | -0.58 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 507.44 M | 383.48 M | 314.71 M | 282.86 M |
| Operating Profit | -199.6 M | -108.14 M | -123.7 M | -102.31 M |
| Net Profit | -187.69 M | -146.37 M | -134.66 M | -99.19 M |
| EPS in Rs | -3.23 | -2.52 | -2.32 | -1.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 893.49 M | 974.76 M | 940.41 M | 1 B |
| Total Liabilities | 237.33 M | 207.82 M | 478.65 M | 472.38 M |
| Equity | 656.15 M | 766.93 M | 461.77 M | 530 M |
| Current Assets | 474.98 M | 449.79 M | 395.46 M | 443.86 M |
| Current Liabilities | 101.28 M | 75.12 M | 74.01 M | 72.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.79 M | -61.32 M | -57.76 M | -33.08 M |
| Investing CF | -77.61 M | 47.83 M | 14.1 M | 44.78 M |
| Financing CF | 11.89 M | 91.54 M | 15.04 M | 6.25 M |
| Free CF | -39.06 M | -67.62 M | -78.01 M | -63.35 M |
| Capex | -24.27 M | -6.3 M | -20.25 M | -30.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 21.85% | 11.26% | — | — |
| Earnings Growth % | -8.7% | -35.75% | — | — |
| Profit Margin % | -38.17% | -42.79% | -35.07% | — |
| Operating Margin % | -28.2% | -39.31% | -36.17% | — |
| Gross Margin % | 75.48% | 75.99% | 75.61% | — |
| EBITDA Margin % | -24.94% | -26.09% | -17.24% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.